JS006
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) [1][2].
Product Specifications
UNSPSC
12352203
Target
Transmembrane Glycoprotein
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Andrew B, et al. Improved treatments for advanced/metastatic cancers with checkpoint inhibitor resistance or resistance susceptibility. WO2023034336A2. 2023-03-09. |[2]JS006.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
22565114 3x 1.0 µg
Gpr4 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)
Sign In for Pricing
View Details 6PCV11-1P-01 100 / PCK
SureSTART 2mL Clear Glass Crimp Top Headspace Vials Level 3
Sign In for Pricing
View Details 6PCV11-1P-02 1000 / PCK
SureSTART 2mL Clear Glass Crimp Top Headspace Vials Level 3
Sign In for Pricing
View Details 6PCV11-1P-03 5000 / PCK
SureSTART 2mL Clear Glass Crimp Top Headspace Vials Level 3
Sign In for Pricing
View Details 
